Packages (Simulation)
Quality Guarantee
Instruction Manual
Certificate
Maybe you can also pay attention to our smart microplate reader
OneStep ELISA Kit for Inter Alpha-Globulin Inhibitor H4 (ITIH4)
IHRP; PK120; H4P; ITIHL1; Plasma Kallikrein-Sensitive Glycoprotein; Plasma kallikrein sensitive glycoprotein 120; Inter-alpha-trypsin inhibitor family heavy chain-related protein
- Product No.OEH776Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length1h10min
- Detection Range0.156-10ug/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.055ug/mL.
- DownloadInstruction Manual
- UOM 48T96T
- FOB
US$
US$
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Inter Alpha-Globulin Inhibitor H4 (ITIH4).
No significant cross-reactivity or interference between Inter Alpha-Globulin Inhibitor H4 (ITIH4) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Inter Alpha-Globulin Inhibitor H4 (ITIH4) and the recovery rates were calculated by comparing the measured value to the expected amount of Inter Alpha-Globulin Inhibitor H4 (ITIH4) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 78-104 | 87 |
| EDTA plasma(n=5) | 80-88 | 85 |
| heparin plasma(n=5) | 92-102 | 97 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Inter Alpha-Globulin Inhibitor H4 (ITIH4) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Inter Alpha-Globulin Inhibitor H4 (ITIH4) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Inter Alpha-Globulin Inhibitor H4 (ITIH4) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-89% | 90-99% | 99-105% | 93-102% |
| EDTA plasma(n=5) | 98-105% | 80-93% | 78-92% | 99-105% |
| heparin plasma(n=5) | 86-95% | 78-99% | 84-94% | 80-102% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well, then add 50µL prepared Detection Reagent A to each well. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
5. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. Pubmed: 23830989 |
| International Journal of Medical Microbiology | Proteomic demonstration of the recurrent presence of inter-alpha-inhibitor H4 heavy-chain during aspergillosis induced in an animal model Pubmed:24360996 |
| Cancer Research and Treatment | Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma pubmed:28724284 |
| Diagnostics | Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J Pubmed: 32585848 |
| Liver Cancer | Biomarkers for locally advanced hepatocellular carcinoma patients treated with liver-directed combined radiotherapy |